The evolution of lung cancer and impact of subclonal selection in TRACERx.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
04 2023
Historique:
received: 21 10 2021
accepted: 02 02 2023
medline: 21 4 2023
pubmed: 13 4 2023
entrez: 12 4 2023
Statut: ppublish

Résumé

Lung cancer is the leading cause of cancer-associated mortality worldwide

Identifiants

pubmed: 37046096
doi: 10.1038/s41586-023-05783-5
pii: 10.1038/s41586-023-05783-5
pmc: PMC10115649
doi:

Substances chimiques

ROS1 protein, human EC 2.7.10.1
RET protein, human EC 2.7.10.1
ALK protein, human EC 2.7.10.1
MET protein, human EC 2.7.10.1
EGFR protein, human EC 2.7.10.1

Banques de données

ClinicalTrials.gov
['NCT01888601']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

525-533

Subventions

Organisme : Cancer Research UK
ID : 25354
Pays : United Kingdom
Organisme : Cancer Research UK
ID : CTRNBC-2022/100001
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 21999
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 24956
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 17786
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : CC2008
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V033077/1
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : CC2041
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 29569
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 30025
Pays : United Kingdom

Investigateurs

John Le Quesne (J)
Peter Van Loo (P)
Amrita Bajaj (A)
Apostolos Nakas (A)
Azmina Sodha-Ramdeen (A)
Keng Ang (K)
Mohamad Tufail (M)
Mohammed Fiyaz Chowdhry (MF)
Molly Scotland (M)
Rebecca Boyles (R)
Sridhar Rathinam (S)
Claire Wilson (C)
Domenic Marrone (D)
Sean Dulloo (S)
Gurdeep Matharu (G)
Jacqui A Shaw (JA)
Joan Riley (J)
Lindsay Primrose (L)
Heather Cheyne (H)
Mohammed Khalil (M)
Shirley Richardson (S)
Tracey Cruickshank (T)
Kayleigh Gilbert (K)
Akshay J Patel (AJ)
Aya Osman (A)
Christer Lacson (C)
Gerald Langman (G)
Helen Shackleford (H)
Madava Djearaman (M)
Salma Kadiri (S)
Angela Leek (A)
Jack Davies Hodgkinson (JD)
Nicola Totten (N)
Angeles Montero (A)
Elaine Smith (E)
Eustace Fontaine (E)
Felice Granato (F)
Helen Doran (H)
Juliette Novasio (J)
Kendadai Rammohan (K)
Leena Joseph (L)
Paul Bishop (P)
Rajesh Shah (R)
Stuart Moss (S)
Vijay Joshi (V)
Philip Crosbie (P)
Fabio Gomes (F)
Kate Brown (K)
Mathew Carter (M)
Anshuman Chaturvedi (A)
Lynsey Priest (L)
Pedro Oliveira (P)
Colin R Lindsay (CR)
Alexandra Clipson (A)
Jonathan Tugwood (J)
Alastair Kerr (A)
Dominic G Rothwell (DG)
Elaine Kilgour (E)
Hugo J W L Aerts (HJWL)
Tom L Kaufmann (TL)
Zoltan Szallasi (Z)
Judit Kisistok (J)
Mateo Sokac (M)
Miklos Diossy (M)
Jonas Demeulemeester (J)
Aengus Stewart (A)
Alastair Magness (A)
Andrew Rowan (A)
Angeliki Karamani (A)
Benny Chain (B)
Brittany B Campbell (BB)
Carla Castignani (C)
Clare E Weeden (CE)
Corentin Richard (C)
David R Pearce (DR)
Despoina Karagianni (D)
Dina Levi (D)
Elena Hoxha (E)
Elizabeth Larose Cadieux (E)
Emma Nye (E)
Eva Grönroos (E)
Felip Gálvez-Cancino (F)
Foteini Athanasopoulou (F)
Francisco Gimeno-Valiente (F)
George Kassiotis (G)
Georgia Stavrou (G)
Gerasimos Mastrokalos (G)
Haoran Zhai (H)
Helen L Lowe (HL)
Ignacio Matos (I)
Jacki Goldman (J)
James L Reading (JL)
Jayant K Rane (JK)
Jie Min Lam (JM)
John A Hartley (JA)
Katey S S Enfield (KSS)
Kayalvizhi Selvaraju (K)
Kevin Litchfield (K)
Kevin W Ng (KW)
Kezhong Chen (K)
Krijn Dijkstra (K)
Krupa Thakkar (K)
Leah Ensell (L)
Mansi Shah (M)
Marcos Vasquez (M)
Maria Litovchenko (M)
Mariana Werner Sunderland (M)
Michelle Leung (M)
Mickael Escudero (M)
Miljana Tanić (M)
Monica Sivakumar (M)
Nnennaya Kanu (N)
Olga Chervova (O)
Olivia Lucas (O)
Othman Al-Sawaf (O)
Philip Hobson (P)
Piotr Pawlik (P)
Richard Kevin Stone (RK)
Robert E Hynds (RE)
Roberto Vendramin (R)
Sadegh Saghafinia (S)
Saioa López (S)
Samuel Gamble (S)
Seng Kuong Anakin Ung (SKA)
Sharon Vanloo (S)
Stefan Boeing (S)
Stephan Beck (S)
Supreet Kaur Bola (SK)
Tamara Denner (T)
Thanos P Mourikis (TP)
Victoria Spanswick (V)
Vittorio Barbè (V)
Wei-Ting Lu (WT)
William Hill (W)
Yin Wu (Y)
Yutaka Naito (Y)
Zoe Ramsden (Z)
Catarina Veiga (C)
Gary Royle (G)
Charles-Antoine Collins-Fekete (CA)
Francesco Fraioli (F)
Paul Ashford (P)
Tristan Clark (T)
Elaine Borg (E)
James Wilson (J)
Alexander James Procter (AJ)
Asia Ahmed (A)
Magali N Taylor (MN)
Arjun Nair (A)
Davide Patrini (D)
Emilie Martinoni Hoogenboom (E)
Fleur Monk (F)
James W Holding (JW)
Junaid Choudhary (J)
Kunal Bhakhri (K)
Marco Scarci (M)
Martin Hayward (M)
Nikolaos Panagiotopoulos (N)
Pat Gorman (P)
Reena Khiroya (R)
Robert Cm Stephens (RC)
Yien Ning Sophia Wong (YNS)
Steve Bandula (S)
Abigail Sharp (A)
Sean Smith (S)
Nicole Gower (N)
Harjot Kaur Dhanda (HK)
Kitty Chan (K)
Camilla Pilotti (C)
Rachel Leslie (R)
Anca Grapa (A)
Hanyun Zhang (H)
Khalid AbdulJabbar (K)
Xiaoxi Pan (X)
Yinyin Yuan (Y)
David Chuter (D)
Mairead MacKenzie (M)
Serena Chee (S)
Aiman Alzetani (A)
Lydia Scarlett (L)
Jennifer Richards (J)
Papawadee Ingram (P)
Silvia Austin (S)
Paulo De Sousa (P)
Simon Jordan (S)
Alexandra Rice (A)
Hilgardt Raubenheimer (H)
Harshil Bhayani (H)
Lyn Ambrose (L)
Anand Devaraj (A)
Hema Chavan (H)
Sofina Begum (S)
Silviu I Buderi (SI)
Daniel Kaniu (D)
Mpho Malima (M)
Sarah Booth (S)
Nadia Fernandes (N)
Pratibha Shah (P)
Chiara Proli (C)
Sarah Danson (S)
Lily Robinson (L)
Craig Dick (C)
Alan Kirk (A)
Mo Asif (M)
Rocco Bilancia (R)
Nikos Kostoulas (N)
Mathew Thomas (M)

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2023. The Author(s).

Références

Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
pubmed: 33538338 doi: 10.3322/caac.21660
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
pubmed: 22397650 doi: 10.1056/NEJMoa1113205 pmcid: 4878653
Jamal-Hanjani, M. et al. Tracking the evolution of non–small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
pubmed: 28445112 doi: 10.1056/NEJMoa1616288
Turajlic, S. et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx Renal. Cell 173, 595–610.e11 (2018).
pubmed: 29656894 doi: 10.1016/j.cell.2018.03.043 pmcid: 5938372
Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127–1133 (2013).
pubmed: 24071851 doi: 10.1038/ng.2762 pmcid: 4320046
Williams, M. J., Werner, B., Barnes, C. P., Graham, T. A. & Sottoriva, A. Identification of neutral tumor evolution across cancer types. Nat. Genet. 48, 238–244 (2016).
pubmed: 26780609 doi: 10.1038/ng.3489 pmcid: 4934603
Reiter, J. G. et al. Minimal functional driver gene heterogeneity among untreated metastases. Science 361, 1033–1037 (2018).
pubmed: 30190408 doi: 10.1126/science.aat7171 pmcid: 6329287
Reiter, J. G. et al. An analysis of genetic heterogeneity in untreated cancers. Nat. Rev. Cancer 19, 639–650 (2019).
pubmed: 31455892 doi: 10.1038/s41568-019-0185-x pmcid: 6816333
Al Bakir, M. et al. The evolution of non-small lung cancer metastases in TRACERx. Nature https://doi.org/10.1038/s41586-023-05729-x (2023).
Rekhtman, N. et al. Unsuspected collision of synchronous lung adenocarcinomas: a potential cause of aberrant driver mutation profiles. J. Thorac. Oncol. 9, e1–e3 (2014).
pubmed: 24346104 doi: 10.1097/JTO.0b013e3182a471c3
Grigoriadis, K. et al. CONIPHER: a computational framework for scalable phylogenetic reconstruction with error correction. Protoc. Exch. https://doi.org/10.21203/rs.3.pex-2158/v1 (2023).
Rahman, N. Realizing the promise of cancer predisposition genes. Nature 505, 302–308 (2014).
pubmed: 24429628 doi: 10.1038/nature12981 pmcid: 4975511
Zaccaria, S. & Raphael, B. J. Accurate quantification of copy-number aberrations and whole-genome duplications in multi-sample tumor sequencing data. Nat. Commun. 11, 4301 (2020).
pubmed: 32879317 doi: 10.1038/s41467-020-17967-y pmcid: 7468132
Lawson, A. R. J. et al. Extensive heterogeneity in somatic mutation and selection in the human bladder. Science 370, 75–82 (2020).
pubmed: 33004514 doi: 10.1126/science.aba8347
Pirie, K. et al. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet 381, 133–141 (2013).
pubmed: 23107252 doi: 10.1016/S0140-6736(12)61720-6 pmcid: 3547248
Byers, T. E., Vena, J. E. & Rzepka, T. F. Predilection of lung cancer for the upper lobes: an epidemiologic inquiry. J. Natl Cancer Inst. 72, 1271–1275 (1984).
pubmed: 6328090
Lee, B. W., Wain, J. C., Kelsey, K. T., Wiencke, J. K. & Christiani, D. C. Association between diet and lung cancer location. Am. J. Respir. Crit. Care Med. 158, 1197–1203 (1998).
pubmed: 9769282 doi: 10.1164/ajrccm.158.4.9804089
Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041.e21 (2017).
pubmed: 29056346 doi: 10.1016/j.cell.2017.09.042 pmcid: 5720395
Watkins, T. B. K. et al. Pervasive chromosomal instability and karyotype order in tumour evolution. Nature 587, 126–132 (2020).
pubmed: 32879494 doi: 10.1038/s41586-020-2698-6 pmcid: 7611706
Mina, M. et al. Conditional selection of genomic alterations dictates cancer evolution and oncogenic dependencies. Cancer Cell 32, 155–168.e6 (2017).
pubmed: 28756993 doi: 10.1016/j.ccell.2017.06.010
de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251–256 (2014).
pubmed: 25301630 doi: 10.1126/science.1253462 pmcid: 4636050
Cross, W. et al. The evolutionary landscape of colorectal tumorigenesis. Nat. Ecol. Evol. 2, 1661–1672 (2018).
pubmed: 30177804 doi: 10.1038/s41559-018-0642-z pmcid: 6152905
Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 50, 1189–1195 (2018).
pubmed: 30013179 doi: 10.1038/s41588-018-0165-1 pmcid: 6072608
Dewhurst, S. M. et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov. 4, 175–185 (2014).
pubmed: 24436049 doi: 10.1158/2159-8290.CD-13-0285 pmcid: 4293454
Satas, G. et al. DeCiFering the elusive cancer cell fraction in tumor heterogeneity and evolution. Cell Syst. https://doi.org/10.1016/j.cels.2021.07.006 (2023).
Martínez-Ruiz, C. et al. Genomic–transcriptomic evolution in lung cancer and metastasis. Nature https://doi.org/10.1038/s41586-023-05706-4 (2023).
Tarabichi, M. et al. Neutral tumor evolution? Nat. Genet. 50, 1630–1633 (2018).
pubmed: 30374075 doi: 10.1038/s41588-018-0258-x pmcid: 6548558
Heide, T. et al. Reply to ‘Neutral tumor evolution?’. Nat. Genet. 50, 1633–1637 (2018).
pubmed: 30374073 doi: 10.1038/s41588-018-0256-z
Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173, 371–385.e18 (2018).
pubmed: 29625053 doi: 10.1016/j.cell.2018.02.060 pmcid: 6029450
Dentro, S. C. et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell 184, 2239–2254.e39 (2021).
pubmed: 33831375 doi: 10.1016/j.cell.2021.03.009 pmcid: 8054914
Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122–128 (2020).
pubmed: 32025013 doi: 10.1038/s41586-019-1907-7 pmcid: 7054212
Sottoriva, A. et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl Acad. Sci. USA 110, 4009–4014 (2013).
pubmed: 23412337 doi: 10.1073/pnas.1219747110 pmcid: 3593922
Shain, A. H. et al. The genetic evolution of metastatic uveal melanoma. Nat. Genet. 51, 1123–1130 (2019).
pubmed: 31253977 doi: 10.1038/s41588-019-0440-9 pmcid: 6632071
Murugaesu, N. et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov. 5, 821–831 (2015).
pubmed: 26003801 doi: 10.1158/2159-8290.CD-15-0412 pmcid: 4529488
Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256–259 (2014).
pubmed: 25301631 doi: 10.1126/science.1256930 pmcid: 4354858
Yates, L. R. et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21, 751–759 (2015).
pubmed: 26099045 doi: 10.1038/nm.3886 pmcid: 4500826
Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal. Cell 173, 581–594.e12 (2018).
pubmed: 29656895 doi: 10.1016/j.cell.2018.03.057 pmcid: 5938365
Mitchell, T. J. et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx Renal. Cell 173, 611–623.e17 (2018).
pubmed: 29656891 doi: 10.1016/j.cell.2018.02.020 pmcid: 5927631
Yoshida, K. et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature 578, 266–272 (2020).
pubmed: 31996850 doi: 10.1038/s41586-020-1961-1 pmcid: 7021511
Berenblum, I. & Shubik, P. A new, quantitative, approach to the study of the stages of chemical carcinogenesis in the mouse’s skin. Br. J. Cancer 1, 383–391 (1947).
pubmed: 18906316 doi: 10.1038/bjc.1947.36 pmcid: 2007527
Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884–i890 (2018).
pubmed: 30423086 doi: 10.1093/bioinformatics/bty560 pmcid: 6129281
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
pubmed: 19451168 doi: 10.1093/bioinformatics/btp324 pmcid: 2705234
Tarasov, A., Vilella, A. J., Cuppen, E., Nijman, I. J. & Prins, P. Sambamba: fast processing of NGS alignment formats. Bioinformatics 31, 2032–2034 (2015).
pubmed: 25697820 doi: 10.1093/bioinformatics/btv098 pmcid: 4765878
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
pubmed: 20644199 doi: 10.1101/gr.107524.110 pmcid: 2928508
Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
pubmed: 19505943 doi: 10.1093/bioinformatics/btp352 pmcid: 2723002
Bergmann, E. A., Chen, B.-J., Arora, K., Vacic, V. & Zody, M. C. Conpair: concordance and contamination estimator for matched tumor–normal pairs. Bioinformatics 32, 3196–3198 (2016).
pubmed: 27354699 doi: 10.1093/bioinformatics/btw389 pmcid: 5048070
Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568–576 (2012).
pubmed: 22300766 doi: 10.1101/gr.129684.111 pmcid: 3290792
Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
pubmed: 23396013 doi: 10.1038/nbt.2514 pmcid: 3833702
Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
pubmed: 20601685 doi: 10.1093/nar/gkq603 pmcid: 2938201
Tate, J. G. et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 47, D941–D947 (2019).
pubmed: 30371878 doi: 10.1093/nar/gky1015
Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat. Genet. 46, 912–918 (2014).
pubmed: 25017105 doi: 10.1038/ng.3036 pmcid: 4753679
Cheng, J. et al. Single-cell copy number variation detection. Genome Biol. 12, R80 (2011).
pubmed: 21854607 doi: 10.1186/gb-2011-12-8-r80 pmcid: 3245619
Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA 107, 16910–16915 (2010).
pubmed: 20837533 doi: 10.1073/pnas.1009843107 pmcid: 2947907
Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. 26, 64–70 (2015).
pubmed: 25319062 doi: 10.1093/annonc/mdu479
Burrell, R. A. et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 494, 492–496 (2013).
pubmed: 23446422 doi: 10.1038/nature11935 pmcid: 4636055
Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 41, e67 (2013).
pubmed: 23303777 doi: 10.1093/nar/gks1443 pmcid: 3616734
Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
pubmed: 32025018 doi: 10.1038/s41586-020-1943-3 pmcid: 7054213
Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).
pubmed: 26899170 doi: 10.1186/s13059-016-0893-4 pmcid: 4762164
Teh, Y. W., Jordan, M. I., Beal, M. J. & Blei, D. M. Hierarchical dirichlet processes. J. Am. Stat. Assoc. 101, 1566–1581 (2006).
doi: 10.1198/016214506000000302
Degasperi, A. et al. Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. Science 376, abl9283 (2022).
doi: 10.1126/science.abl9283
McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7, 283ra54 (2015).
pubmed: 25877892 doi: 10.1126/scitranslmed.aaa1408 pmcid: 4636056
Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396–398 (2014).
pubmed: 24633410 doi: 10.1038/nmeth.2883 pmcid: 4864026
Myers, M. A., Satas, G. & Raphael, B. J. CALDER: inferring phylogenetic trees from longitudinal tumor samples. Cell Syst. 8, 514–522.e5 (2019).
pubmed: 31229560 doi: 10.1016/j.cels.2019.05.010 pmcid: 7263382
Deshwar, A. G. et al. PhyloWGS: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. Genome Biol. 16, 35 (2015).
pubmed: 25786235 doi: 10.1186/s13059-015-0602-8 pmcid: 4359439
El-Kebir, M., Oesper, L., Acheson-Field, H. & Raphael, B. J. Reconstruction of clonal trees and tumor composition from multi-sample sequencing data. Bioinformatics 31, i62–i70 (2015).
pubmed: 26072510 doi: 10.1093/bioinformatics/btv261 pmcid: 4542783
Satas, G. & Raphael, B. J. Tumor phylogeny inference using tree-constrained importance sampling. Bioinformatics 33, i152–i160 (2017).
pubmed: 28882002 doi: 10.1093/bioinformatics/btx270 pmcid: 5870673
El-Kebir, M. et al. Complexity and algorithms for copy-number evolution problems. Algorithms Mol. Biol. 12, 13 (2017).
pubmed: 28515774 doi: 10.1186/s13015-017-0103-2 pmcid: 5433102
Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012).
pubmed: 22544022 doi: 10.1038/nbt.2203 pmcid: 4383288
Forbes, S. A. et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805–D811 (2015).
pubmed: 25355519 doi: 10.1093/nar/gku1075
Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014).
pubmed: 24390350 doi: 10.1038/nature12912 pmcid: 4048962
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525 (2012).
doi: 10.1038/nature11404
Collisson, E. et al. Comprehensive molecular profiling of lung adenocarcinoma: The Cancer Genome Atlas Research Network. Nature 511, 543–550 (2014).
doi: 10.1038/nature13385
Campbell, J. D. et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat. Genet. 48, 607–616 (2016).
pubmed: 27158780 doi: 10.1038/ng.3564 pmcid: 4884143
Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 1073–1081 (2009).
pubmed: 19561590 doi: 10.1038/nprot.2009.86
Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. https://doi.org/10.1002/0471142905.hg0720s76 (2013).
Schwarz, J. M., Rödelsperger, C., Schuelke, M. & Seelow, D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat. Methods 7, 575–576 (2010).
pubmed: 20676075 doi: 10.1038/nmeth0810-575
Berger, A. H. et al. High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell 30, 214–228 (2016).
pubmed: 27478040 doi: 10.1016/j.ccell.2016.06.022 pmcid: 5003022
Sanchez-Vega, F. et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell 173, 321–337.e10 (2018).
pubmed: 29625050 doi: 10.1016/j.cell.2018.03.035 pmcid: 6070353
Canisius, S., Martens, J. W. M. & Wessels, L. F. A. A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence. Genome Biol. 17, 261 (2016).
pubmed: 27986087 doi: 10.1186/s13059-016-1114-x pmcid: 5162102
Frankell, A. M., Colliver, E., Mcgranahan, N. & Swanton, C. cloneMap: a R package to visualise clonal heterogeneity. Preprint at bioRxiv https://doi.org/10.1101/2022.07.26.501523 (2022).
Broad Institute TCGA Genome Data Analysis Center (2016): SNP6 Copy number analysis (GISTIC2) (Broad Institute of MIT and Harvard, 2016).
Royston, P. & Parmar, M. K. B. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med. Res. Methodol. 13, 152 (2013).
pubmed: 24314264 doi: 10.1186/1471-2288-13-152 pmcid: 3922847
Uno, H. et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J. Clin. Oncol. 32, 2380–2385 (2014).
pubmed: 24982461 doi: 10.1200/JCO.2014.55.2208 pmcid: 4105489
Liang, F., Zhang, S., Wang, Q. & Li, W. Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer. Ann. Oncol. 29, 1320–1324 (2018).
pubmed: 29788167 doi: 10.1093/annonc/mdy075

Auteurs

Alexander M Frankell (AM)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Michelle Dietzen (M)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Maise Al Bakir (M)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Emilia L Lim (EL)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Takahiro Karasaki (T)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.

Sophia Ward (S)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Advanced Sequencing Facility, The Francis Crick Institute, London, UK.

Selvaraju Veeriah (S)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Emma Colliver (E)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Ariana Huebner (A)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Abigail Bunkum (A)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.
Computational Cancer Genomics Research Group, University College London Cancer Institute, London, UK.

Mark S Hill (MS)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Kristiana Grigoriadis (K)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

David A Moore (DA)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Department of Cellular Pathology, University College London Hospitals, London, UK.

James R M Black (JRM)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Wing Kin Liu (WK)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.

Kerstin Thol (K)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Oriol Pich (O)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Thomas B K Watkins (TBK)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Cristina Naceur-Lombardelli (C)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Daniel E Cook (DE)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Roberto Salgado (R)

Department of Pathology, ZAS Hospitals, Antwerp, Belgium.
Division of Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Gareth A Wilson (GA)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Chris Bailey (C)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Mihaela Angelova (M)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Robert Bentham (R)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Carlos Martínez-Ruiz (C)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Christopher Abbosh (C)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Andrew G Nicholson (AG)

Department of Histopathology, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
National Heart and Lung Institute, Imperial College London, London, UK.

John Le Quesne (J)

Cancer Research UK Beatson Institute, Glasgow, UK.
School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Pathology Department, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK.

Dhruva Biswas (D)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Bill Lyons Informatics Centre, University College London Cancer Institute, London, UK.

Rachel Rosenthal (R)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Clare Puttick (C)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Sonya Hessey (S)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.
Computational Cancer Genomics Research Group, University College London Cancer Institute, London, UK.

Claudia Lee (C)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Division of Medicine, University College London, London, UK.

Paulina Prymas (P)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Antonia Toncheva (A)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Jon Smith (J)

Scientific Computing, The Francis Crick Institute, London, UK.

Wei Xing (W)

Scientific Computing, The Francis Crick Institute, London, UK.

Jerome Nicod (J)

Advanced Sequencing Facility, The Francis Crick Institute, London, UK.

Gillian Price (G)

Department of Medical Oncology, Aberdeen Royal Infirmary NHS Grampian, Aberdeen, UK.
University of Aberdeen, Aberdeen, UK.

Keith M Kerr (KM)

University of Aberdeen, Aberdeen, UK.
Department of Pathology, Aberdeen Royal Infirmary NHS Grampian, Aberdeen, UK.

Babu Naidu (B)

Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.

Gary Middleton (G)

University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Kevin G Blyth (KG)

Cancer Research UK Beatson Institute, Glasgow, UK.
School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Queen Elizabeth University Hospital, Glasgow, UK.

Dean A Fennell (DA)

University of Leicester, Leicester, UK.
University Hospitals of Leicester NHS Trust, Leicester, UK.

Martin D Forster (MD)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Department of Oncology, University College London Hospitals, London, UK.

Siow Ming Lee (SM)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Department of Oncology, University College London Hospitals, London, UK.

Mary Falzon (M)

Department of Cellular Pathology, University College London Hospitals, London, UK.

Madeleine Hewish (M)

Royal Surrey Hospital, Royal Surrey Hospitals NHS Foundation Trust, Guilford, UK.
University of Surrey, Guilford, UK.

Michael J Shackcloth (MJ)

Liverpool Heart and Chest Hospital, Liverpool, UK.

Eric Lim (E)

Academic Division of Thoracic Surgery, Imperial College London, London, UK.
Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Sarah Benafif (S)

Department of Oncology, University College London Hospitals, London, UK.

Peter Russell (P)

Princess Alexandra Hospital, The Princess Alexandra Hospital NHS Trust, Harlow, UK.

Ekaterini Boleti (E)

Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK.

Matthew G Krebs (MG)

Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.

Jason F Lester (JF)

Singleton Hospital, Swansea Bay University Health Board, Swansea, UK.

Dionysis Papadatos-Pastos (D)

Department of Oncology, University College London Hospitals, London, UK.

Tanya Ahmad (T)

Department of Oncology, University College London Hospitals, London, UK.

Ricky M Thakrar (RM)

Department of Thoracic Medicine, University College London Hospitals, London, UK.
Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.

David Lawrence (D)

Department of Thoracic Surgery, University College London Hospital NHS Trust, London, UK.

Neal Navani (N)

Department of Thoracic Medicine, University College London Hospitals, London, UK.
Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.

Sam M Janes (SM)

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.

Caroline Dive (C)

Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, Manchester, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University of Manchester, Manchester, UK.

Fiona H Blackhall (FH)

Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.

Yvonne Summers (Y)

Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.

Judith Cave (J)

Department of Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Teresa Marafioti (T)

Department of Cellular Pathology, University College London Hospitals, London, UK.

Javier Herrero (J)

Bill Lyons Informatics Centre, University College London Cancer Institute, London, UK.

Sergio A Quezada (SA)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Immune Regulation and Tumour Immunotherapy Group, Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.

Karl S Peggs (KS)

Department of Haematology, University College London Hospitals, London, UK.
Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.

Roland F Schwarz (RF)

Institute for Computational Cancer Biology, Center for Integrated Oncology (CIO), Cancer Research Center Cologne Essen (CCCE), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Berlin Institute for the Foundations of Learning and Data (BIFOLD), Berlin, Germany.

Peter Van Loo (P)

Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.

Daniël M Miedema (DM)

LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Oncode Institute, Amsterdam, The Netherlands.

Nicolai J Birkbak (NJ)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark.

Crispin T Hiley (CT)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Allan Hackshaw (A)

Cancer Research UK and UCL Cancer Trials Centre, London, UK.

Simone Zaccaria (S)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Computational Cancer Genomics Research Group, University College London Cancer Institute, London, UK.

Mariam Jamal-Hanjani (M)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. m.jamal-hanjani@ucl.ac.uk.
Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK. m.jamal-hanjani@ucl.ac.uk.
Department of Oncology, University College London Hospitals, London, UK. m.jamal-hanjani@ucl.ac.uk.

Nicholas McGranahan (N)

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.
Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.

Charles Swanton (C)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. charles.swanton@crick.ac.uk.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. charles.swanton@crick.ac.uk.
Department of Oncology, University College London Hospitals, London, UK. charles.swanton@crick.ac.uk.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH